Molecular spectroscopy of blood plasma differentiates metabolic dysfunction-associated steatohepatitis from steatosis
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F67985882%3A_____%2F25%3A00638217" target="_blank" >RIV/67985882:_____/25:00638217 - isvavai.cz</a>
Alternative codes found
RIV/00216208:11110/25:10500554 RIV/60461373:22340/25:43932263 RIV/00064165:_____/25:10500554
Result on the web
<a href="https://doi.org/10.1186/s12967-025-06885-6" target="_blank" >https://doi.org/10.1186/s12967-025-06885-6</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1186/s12967-025-06885-6" target="_blank" >10.1186/s12967-025-06885-6</a>
Alternative languages
Result language
angličtina
Original language name
Molecular spectroscopy of blood plasma differentiates metabolic dysfunction-associated steatohepatitis from steatosis
Original language description
Background: Vibrational and chiroptical spectroscopy of blood plasma is an advanced experimental diagnostic approach that allows the identification of disease-specific molecular patterns. This study aimed to test its potential to distinguish between different stages of metabolic dysfunction-associated steatotic liver disease (MASLD) including liver fibrosis. Methods: We analyzed blood plasma samples from 29 patients with metabolic dysfunction-associated steatohepatitis (MASH) and 24 MASLD patients with simple steatosis using Fourier-transform infrared (FTIR) spectroscopy, Raman spectroscopy and electronic circular dichroism (ECD) spectroscopy to distinguish: (i) MASH, (ii) MASH with moderate to advanced fibrosis, and (iii) overall fibrosis. Results: FTIR spectroscopy distinguished MASH from simple steatosis with a sensitivity of 73% and a specificity of 92%, with an area under the receiver operating characteristic curve (AUROC) of 0.92, p < 0.001. In addition, FTIR spectroscopy identified MASH with moderate to advanced fibrosis (F2–3) from MASH/steatosis with no to mild fibrosis (F0–1) with a sensitivity of 87% and specificity of 78% (AUROC 0.91, p < 0.001). Furthermore, regardless of the MASH/steatosis diagnosis, fibrosis (F1–3) was distinguished from F0 by the combination of data from the three spectroscopic methods with a sensitivity of 79% and a specificity of 88% (AUROC 0.91, p < 0.001). Both FTIR and Raman spectroscopy alone discriminated all target groups with an AUROC > 0.82. Conclusions: This pilot study revealed the potential of blood plasma spectroscopy to identify and differentiate patients with various stages of MASLD
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
10306 - Optics (including laser optics and quantum optics)
Result continuities
Project
<a href="/en/project/NU23-01-00288" target="_blank" >NU23-01-00288: Complex lifestyle modification in the treatment of non-alcoholic fatty liver disease</a><br>
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2025
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Journal of Translational Medicine
ISSN
1479-5876
e-ISSN
1479-5876
Volume of the periodical
23
Issue of the periodical within the volume
1
Country of publishing house
GB - UNITED KINGDOM
Number of pages
11
Pages from-to
868
UT code for WoS article
001546947200008
EID of the result in the Scopus database
2-s2.0-105012898836